目的 探討銀花泌炎靈片聯(lián)合注射用頭孢噻肟鈉治療急性腎盂腎炎的臨床療效。方法 選擇2018年6月-2019年6月在駐馬店市中心醫(yī)院治療的急性腎盂腎炎患者94例，根據(jù)用藥的差別分為對照組（47例）和治療組（47例）。對照組患者靜脈滴注注射用頭孢噻肟鈉，2.0 g加入生理鹽水100 mL，2次/d；治療組在對照組的基礎(chǔ)上口服銀花泌炎靈片，4片/次，4次/d。兩組患者均治療14 d。觀察兩組患者臨床療效，同時比較治療前后兩組患者癥候積分，血清轉(zhuǎn)化生長因子β1（TGF-β1）、白細(xì)胞介素-6（IL-6）、組織型-纖維蛋白溶解酶原激活劑（t-PA）、白細(xì)胞介素-17（IL-17）、乙酰-β-D-葡萄糖苷酶（NAG）、β2-微球蛋白（β2-MG）水平，以及SF-36、PSQI和APACHE Ⅱ評分。結(jié)果 治療后，對照組臨床有效率為80.85%，顯著低于治療組的97.87%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。經(jīng)治療，兩組患者癥候積分及SF-36、PSQI和APACHE Ⅱ評分均顯著降低（P<0.05），且治療組患者比對照組降低更明顯（P<0.05）。經(jīng)治療，兩組患者血清β2-MG、IL-6、TGF-β1、IL-17、NAG水平均顯著降低（P<0.05），而t-PA水平均明顯升高（P<0.05），且治療組比對照組改善更明顯（P<0.05）。結(jié)論 銀花泌炎靈片聯(lián)合頭孢噻肟治療急性腎盂腎炎可有效改善患者臨床癥狀，有利于患者生活質(zhì)量的提高。

Objective To explore the clinical effect of Yinhua Miyanling Tablets combined with cefotaxime in treatment of acute pyelonephritis. Methods Patients (94 cases) with acute pyelonephritis in Zhumadian Central Hospital from June 2018 to June 2019 were divided into control (47 cases) and treatment (47 cases) groups based on different treatments. Patients in the control group were iv administered with Cefotaxime Sodium for injection, 2.0 g added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Yinhua Miyanling Tablets on the basis of the control group, 4 tablets/time, 4 times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the symptom scores, the serum levels of β2-MG, IL-6, TGF-β1, IL-17 and NAG, SF-36, PSQI, and APACHE Ⅱ scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.85%, which was significantly lower than 97.87% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the symptom scores, SF-36, PSQI, and APACHE Ⅱ scores in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum levels of β2-MG, IL-6, TGF-β1, IL-17, and NAG in two groups were significantly decreased, but the t-PA levels were significantly increased (P<0.05), and these serological indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Yinhua Miyanling Tablets combined with cefotaxime in treatment of acute pyelonephritis can effectively improve the clinical symptoms and the quality of life of patients.

R983